Literature DB >> 19646355

Primary angiitis of the central nervous system.

A Néel1, C Pagnoux.   

Abstract

Primary angiitis of the central nervous system (PACNS) was first identified half a century ago, but it remains a rare and challenging disease. However, important advances have been made in the field of PACNS, mainly through recently published retrospective analyses of large groups of PACNS patients, and the consideration of reversible cerebral vasoconstriction syndrome as a distinct entity. Clinical manifestations of PACNS are variable and non-specific. Even though neuroimaging can be suggestive of vasculitis, only a leptomeningeal biopsy can definitively confirm vasculitis. However, a brain sample is taken in less than half the patients and cannot further help to distinguish between PACNS and secondary vasculitis of the central nervous system. Hence, physicians should be aware of all alternative diagnoses and PACNS mimickers, which are now well-known. Whereas prognosis now appears to be much better than for the first reported cases, probably attributable to the use of corticosteroids and immunosuppressants, mainly cyclophosphamide, the optimal therapeutic regimen, potentially based on each patient's characteristics, and its duration remain to be determined. Only multicenter studies and prospective therapeutic trials will be able to clarify these issues on therapy and eventually provide some data on PACNS physiopathogenesis, which remains a poorly explored domain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19646355

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  9 in total

Review 1.  Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls.

Authors:  P Berlit; M Kraemer
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 2.  The spectrum of CNS vasculitis in children and adults.

Authors:  Marinka Twilt; Susanne M Benseler
Journal:  Nat Rev Rheumatol       Date:  2011-12-20       Impact factor: 20.543

3.  Neuroradiologic Characteristics of Primary Angiitis of the Central Nervous System According to the Affected Vessel Size.

Authors:  Christian Thaler; Ann-Katrin Kaufmann-Bühler; Tserenchunt Gansukh; Amarjargal Gansukh; Simon Schuster; Henrike Bachmann; Götz Thomalla; Tim Magnus; Jakob Matschke; Jens Fiehler; Susanne Siemonsen
Journal:  Clin Neuroradiol       Date:  2017-09-05       Impact factor: 3.649

4.  Three cases of CLIPPERS: a serial clinical, laboratory and MRI follow-up study.

Authors:  O Kastrup; J van de Nes; T Gasser; K Keyvani
Journal:  J Neurol       Date:  2011-05-10       Impact factor: 4.849

5.  Primary and secondary central nervous system vasculitis: clinical manifestations, laboratory findings, neuroimaging, and treatment analysis.

Authors:  Olga Vera-Lastra; Jesús Sepúlveda-Delgado; María del Pilar Cruz-Domínguez; Gabriela Medina; Moisés Casarrubias-Ramírez; Luis E Molina-Carrión; Luis F Pineda-Galindo; Arturo Olvera-Acevedo; Claudia Hernández-Gonzalez; Luis J Jara
Journal:  Clin Rheumatol       Date:  2014-11-27       Impact factor: 2.980

6.  Cerebral vasculitis presenting as a stroke.

Authors:  Maxine Montefort; Umesh Dashora; Muhammad Chowdhury
Journal:  BMJ Case Rep       Date:  2012-11-27

7.  New onset refractory status epilepticus due to primary angiitis of the central nervous system.

Authors:  Rawan K Matar; Bader Alshamsan; Saleh Alsaleh; Hindi Alhindi; Khalid O Alahmedi; Sami Khairy; Salah Baz
Journal:  Epilepsy Behav Case Rep       Date:  2017-08-19

8.  Cyclophosphamide responsive primary angiitis of the CNS in a 61-year-old female.

Authors:  Jay Rosenberg; Ali Mahta; Kavya Koppula; Ewa Borys; Santosh Kesari
Journal:  Clin Neuropathol       Date:  2013 Jan-Feb       Impact factor: 1.368

9.  Role of magnetic resonance imaging in the diagnosis of primary central nervous system angiitis.

Authors:  Lei Niu; Liwei Wang; Xindao Yin; Xiao-Feng Li; Feng Wang
Journal:  Exp Ther Med       Date:  2017-06-08       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.